Therapeutic options for relapsed acute myeloid leukemia after hematopoietic stem cell transplantation.

IF 2.1 4区医学 Q2 HEMATOLOGY

Expert Review of Hematology Pub Date : 2025-08-13 DOI:10.1080/17474086.2025.2547866

Alkim Yolcu, Elifcan Aladag Karakulak, Hakan Goker

{"title":"Therapeutic options for relapsed acute myeloid leukemia after hematopoietic stem cell transplantation.","authors":"Alkim Yolcu, Elifcan Aladag Karakulak, Hakan Goker","doi":"10.1080/17474086.2025.2547866","DOIUrl":null,"url":null,"abstract":"Introduction: Acute myeloid leukemia (AML) is a malignant clonal hematopoietic cell disorder, characterized by impaired hematopoiesis and bone marrow failure. Allogeneic hematopoietic stem cell transplantation (allo-HCT) is an established therapy with curative potential. Post-transplant relapse does occur and has dismal prognosis, which is the main cause of death after allo-HCT. Relapses after allo-HCT in AML do cause standard treatment approaches challenging, which often necessitate individualized treatment modalities and large prospective clinical trials are needed to delineate standardized therapies. The management of AML relapse after allo-HCT remains a clinical challenge, and no standardized treatment approach currently exists.Areas covered: This review provides an overview of the available therapeutic options for patients with relapsed AML after allo-HCT. It provides a beneficial framework on the optimal treatment approach, including factors that influence drug preferences. A search of papers published up to March 2025 was conducted on PubMed using the keywords.Expert opinion: Combining chemotherapy, targeted agents, and immunotherapy can increase the rate of response and survival for relapsed AML after allo-HCT. Future research is needed to develop strategies that can reduce the risk of relapse after allo-HCT. Individualization of treatments and exploration of combination therapies are potential approaches for improving efficacy.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17474086.2025.2547866","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Acute myeloid leukemia (AML) is a malignant clonal hematopoietic cell disorder, characterized by impaired hematopoiesis and bone marrow failure. Allogeneic hematopoietic stem cell transplantation (allo-HCT) is an established therapy with curative potential. Post-transplant relapse does occur and has dismal prognosis, which is the main cause of death after allo-HCT. Relapses after allo-HCT in AML do cause standard treatment approaches challenging, which often necessitate individualized treatment modalities and large prospective clinical trials are needed to delineate standardized therapies. The management of AML relapse after allo-HCT remains a clinical challenge, and no standardized treatment approach currently exists.

Areas covered: This review provides an overview of the available therapeutic options for patients with relapsed AML after allo-HCT. It provides a beneficial framework on the optimal treatment approach, including factors that influence drug preferences. A search of papers published up to March 2025 was conducted on PubMed using the keywords.

Expert opinion: Combining chemotherapy, targeted agents, and immunotherapy can increase the rate of response and survival for relapsed AML after allo-HCT. Future research is needed to develop strategies that can reduce the risk of relapse after allo-HCT. Individualization of treatments and exploration of combination therapies are potential approaches for improving efficacy.

查看原文本刊更多论文

造血干细胞移植后复发性急性髓性白血病的治疗选择。

简介：急性髓性白血病（AML）是一种恶性克隆性造血细胞疾病，以造血功能受损和骨髓衰竭为特征。同种异体造血干细胞移植（allo-HCT）是一种具有治疗潜力的成熟疗法。移植后确实会复发，预后不佳，这是同种异体移植后死亡的主要原因。AML患者在接受同种异体hct治疗后复发确实会导致标准治疗方法具有挑战性，这通常需要个性化的治疗方式，并且需要大规模的前瞻性临床试验来描述标准化治疗方法。同种异体hct后AML复发的管理仍然是一个临床挑战，目前没有标准化的治疗方法。涵盖领域：本综述概述了同种异体hct后复发性AML患者的可用治疗选择。它为最佳治疗方法提供了一个有益的框架，包括影响药物偏好的因素。在PubMed上使用关键词搜索到2025年3月之前发表的论文。专家意见：联合化疗、靶向药物和免疫治疗可以提高异基因hct后复发AML的反应率和生存率。未来的研究需要制定策略，以降低allo-HCT后复发的风险。个体化治疗和探索联合治疗是提高疗效的潜在途径。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Hematology HEMATOLOGY-

CiteScore

4.70

自引率

3.60%

发文量

审稿时长

6-12 weeks

期刊介绍： Advanced molecular research techniques have transformed hematology in recent years. With improved understanding of hematologic diseases, we now have the opportunity to research and evaluate new biological therapies, new drugs and drug combinations, new treatment schedules and novel approaches including stem cell transplantation. We can also expect proteomics, molecular genetics and biomarker research to facilitate new diagnostic approaches and the identification of appropriate therapies. Further advances in our knowledge regarding the formation and function of blood cells and blood-forming tissues should ensue, and it will be a major challenge for hematologists to adopt these new paradigms and develop integrated strategies to define the best possible patient care. Expert Review of Hematology (1747-4086) puts these advances in context and explores how they will translate directly into clinical practice.